Real-World data reveals which prostate cancer drug helps men live longer
NCT ID NCT05968599
Summary
This study looked at real-world medical records to compare two common drugs for advanced prostate cancer: enzalutamide and abiraterone. Researchers analyzed data from over 2,700 men who had not yet received chemotherapy to see which treatment was associated with longer survival and how long patients stayed on the medication. The goal was to understand the real-world effectiveness of these standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Inc
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.